| Literature DB >> 2543207 |
A Lipton1, H A Harvey, B Walker, R Dixon, D Valdivia, S Barnes, R Gordon, D White-Hershey, M J Bartholomew, N Warzawski.
Abstract
One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vincristine, and etoposide (VP-16)] chemotherapy +/- RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2543207 DOI： 10.1097/00000421-198906000-00016
Source DB: PubMed Journal: Am J Clin Oncol ISSN： 0277-3732 Impact factor: 2.339